← Back to Search

Monoclonal Antibodies

Mavrilimumab for Pneumonia

Phase 2
Waitlist Available
Led By Kristin Hudock, MD
Research Sponsored by Kristin Hudock
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days

Summary

The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe COVID-19 pneumonia and clinical and biological features of hyper-inflammation.

Eligible Conditions
  • Pneumonia
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Measure
Secondary study objectives
Measures

Side effects data

From 2021 Phase 2 trial • 40 Patients • NCT04399980
21%
Acute Respiratory Syndrome
16%
Hypoxia - Worsening
16%
Acute Kidney Injury
11%
Acute Respiratory Distress Syndrome
11%
anemia
11%
Arrhythmia
11%
Pneumonia
5%
Headache
5%
Chronic Respiratory Failure
5%
Elevated WBC
5%
Shock
5%
Pulmonary Embolism
5%
Hypotension
5%
Clot
5%
Elevated Ferritin
5%
Elevated CRP
5%
Delirium
5%
Worsening D Dimer
5%
Fever
100%
80%
60%
40%
20%
0%
Study treatment Arm
Control
Intervention

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MavrilimumabExperimental Treatment1 Intervention
Mavrilimumab treatment infusion
Group II: PlaceboPlacebo Group1 Intervention
Placebo infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mavrilimumab
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Kristin HudockLead Sponsor
Kiniksa Pharmaceuticals, Ltd.Industry Sponsor
8 Previous Clinical Trials
1,372 Total Patients Enrolled
3 Trials studying Pneumonia
857 Patients Enrolled for Pneumonia
Kristin Hudock, MDPrincipal Investigator - University of Cincinnati
University of Cincinnati Medical Center
Georgetown University School Of Medicine (Medical School)
Georgetown University Medical Center (Residency)
~11 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top